Product image of Pamorelin (Triptorelin) supplied by GNH India

Pamorelin

Active Ingredient:
Triptorelin
Origin:
EU

Pamorelin (Triptorelin)

Triptorelin, the active ingredient in Pamorelin, is a GnRH agonist presented as a 0.1 mg/3 ml solution for subcutaneous injection use. It is employed in the management of hormone‑dependent conditions such as prostate cancer, endometriosis and uterine fibroids in adults.

GNH India supplies Pamorelin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Manufacturer / TM Owner

Ipsen Pharma

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Pamorelin is a GnRH‑agonist that modulates the hormonal axis in several disease families.

  • Prostate cancer: provides androgen suppression to slow tumor progression.
  • Endometriosis: induces a hypo‑estrogenic state that reduces pelvic pain and lesion growth.
  • Uterine fibroids: lowers estrogen levels to decrease fibroid size and related bleeding.

How It Works

  • Triptorelin is a synthetic decapeptide that binds with high affinity to pituitary gonadotropin‑releasing hormone (GnRH) receptors, initially stimulating a surge of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) followed by receptor desensitisation and sustained suppression of LH, FSH and downstream sex steroids such as testosterone and estradiol.

Side Effects

Adverse reactions to Pamorelin are reported across a spectrum of frequency.

Common Side Effects

  • Hot flashes: transient warmth and sweating.
  • Injection site pain: mild to moderate discomfort at the injection site.
  • Headache: occasional tension‑type headache.
  • Fatigue: general tiredness.
  • Nausea: mild, self‑limiting gastrointestinal upset.

Serious or Rare Side Effects

  • Cardiovascular events: myocardial infarction or stroke.
  • Severe allergic reaction: anaphylaxis or angio‑edema.
  • Bone loss: accelerated osteoporosis leading to fractures.
  • Hormonal crisis: acute adrenal insufficiency in vulnerable patients.
  • Pituitary apoplexy: sudden hemorrhage within the pituitary gland.

Precautions & Warnings

When prescribing Pamorelin, clinicians should consider several safety aspects.

  • Cardiovascular assessment: evaluate history of heart disease before initiating therapy.
  • Bone health monitoring: perform baseline densitometry and repeat as needed.
  • Hormone‑dependent tumor surveillance: watch for flare‑up of hormone‑sensitive lesions.
  • Pregnancy and lactation: avoid use in women who are pregnant or breastfeeding.
  • Storage: Store below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Triptorelin may interact with other medicines that influence hormonal or cardiovascular status.

Major Interactions (Avoid)

  • Anti‑androgens: may blunt the intended androgen‑suppression effect.
  • CYP450 inducers: can alter the metabolic clearance of concomitant drugs.

Moderate Interactions (Monitor Closely)

  • Anticoagulants: increased risk of bleeding with injection‑site bruising.
  • Hormone replacement therapy: may require dose adjustments.
  • GnRH antagonists: concurrent use can produce unpredictable hormone levels.

Frequently Asked Questions

Pamorelin, containing the GnRH agonist triptorelin, is indicated for androgen suppression in advanced prostate cancer, for creating a hypo‑estrogenic environment in endometriosis, and for reducing estrogen‑driven uterine fibroid growth. These uses rely on its ability to lower circulating sex‑steroid levels.

Triptorelin mimics natural GnRH and binds to pituitary GnRH receptors. After an initial hormone surge, the receptors become desensitised, leading to sustained suppression of luteinizing hormone, follicle‑stimulating hormone and downstream sex steroids such as testosterone and estradiol, which drives its therapeutic effects.

The prescribed dose of Pamorelin is determined by the treating physician based on the specific indication, patient characteristics and treatment protocol. Clinicians set the dosing schedule and formulation strength according to current clinical guidelines.

Pamorelin is contraindicated in pregnancy and is not recommended for breastfeeding women because it can suppress sex‑steroid production, potentially affecting fetal development and milk composition. Women of childbearing potential should use effective contraception during treatment.

To order Pamorelin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Pamorelin is a synthetic GnRH agonist similar to leuprolide and goserelin, offering comparable efficacy in hormone suppression. Differences may lie in dosing frequency, formulation concentration and approved indications, allowing clinicians to choose based on patient convenience and therapeutic goals.

Pamorelin should be stored below 25°C in its original packaging, protected from moisture and direct sunlight. Do not freeze the product, and keep it out of reach of children.

Pamorelin is supplied as a sterile solution for subcutaneous injection. A healthcare professional prepares the dose according to the prescribing information and injects it into the subcutaneous tissue, typically in the abdomen or thigh, following aseptic technique.

Serious risks include cardiovascular events such as myocardial infarction or stroke, severe allergic reactions like anaphylaxis, rapid bone loss leading to fractures, and rare occurrences of pituitary apoplexy. Patients should be monitored closely for these events throughout therapy.

Pamorelin is contraindicated in individuals with known hypersensitivity to triptorelin or any excipients, in pregnant or nursing women, and in patients with uncontrolled cardiovascular disease or severe osteoporosis where further bone loss would be hazardous.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Triptorelin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT